A RECENT study has revealed that a significant proportion of adults prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight management discontinue treatment within a year, with discontinuation rates notably higher among those without Type 2 diabetes
DB enhances insulin release through mechanisms involving KATP channels, bitter taste receptor signaling, and intraislet GLP-1 secretion
This positive correlation is depicted by the green line in Fig
Others find that combining semaglutide with lifestyle changesstructured exercise, protein intake, strength trainingreignites progress without requiring a higher dose
While they share a common mechanism of action, enhancing glucose-dependent insulin secretion, reducing glucagon secretion, and slowing gastric emptying, there are notable differences in their efficacy and usage in weight management